HWM
SPRY icon

Hohimer Wealth Management’s ARS Pharmaceuticals SPRY Stock Holding History

Hohimer Wealth Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,000
Closed -$42K – 217
2022
Q1 		$42K Buy
12,000
+2,000
+20% +$8.71K 0.01% 205
2021
Q4 		$67K Sell
10,000
-7,077
-41% -$57.5K 0.01% 196
2021
Q3 		$170K Buy
+17,077
New +$421K 0.04% 171

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hohimer Wealth Management's SPRY Position: Q2 2022 in Review

Hohimer Wealth Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2022, closing a stake of 12,000 shares — an estimated $42K sold.

Hohimer Wealth Management first reported a position in SPRY in Q3 2021 and held it in 3 quarters. The position peaked at $170K in Q3 2021. 64 funds tracked by Wall St. Rank hold SPRY as of Q2 2022.

  • Hohimer Wealth Management reported no remaining ARS Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Hohimer Wealth Management sold 12,000 ARS Pharmaceuticals shares in Q2 2022, an estimated $42K.
  • Hohimer Wealth Management first reported a position in ARS Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Hohimer Wealth Management's ARS Pharmaceuticals position peaked at $170K in Q3 2021.
  • 64 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2022.

Based on Hohimer Wealth Management's 13F filing for Q2 2022, filed 25 Jul 2022.